Of the hypoglycemic agents that have been used clinically, biguanides and sulfonylureas have pharmacologic activity with respect to noninsulin-dependent diabetes mellitus (NIDDM), but they are ineffective in the treatment of insulin-dependent diabetes mellitus (IDDM). b-Glucosidase inhibitors are useful as adjuncts to dietary therapies. Although insulin is the most effective drug for both types of diabetes, oral administration is not recommended. Efficient oral drugs for the treatment of both types of diabetes would therefore be useful.
MeOH at room temperature. The aqueous concentrate was acidified to pH 3.0 with 10% HCl, and the resulting precipitate was filtered out. The filtrate was extracted three times with CH 2 Cl 2 . The aqueous layer was made strongly alkaline with K 2 CO 3 and extracted three times with CH 2 Cl 2 . The CH 2 Cl 2 layers were combined, dried over Na 2 SO 4 , and concentrated in vacuo, yielding a crude base (yield, 18.2 g, 1.8%). The crude base was separated by chromatography on a silica gel with a solvent gradient of CH 2 Cl 2 : MeOH : 25% NH 4 OH. The eluted volume of each fraction was 100 ml.
Purification of (؊)-Multiflorine The crude alkaloid mixture was separated on silica gel column chromatography and purified by preparative HPLC, resulting in purified (Ϫ)-multiflorine.
(Ϫ)-Multiflorine ( Dehydrogenation of (؊)-Multiflorine A 1.6 M n-BuLi solution in hexane was added to diisopropylamine (45 mg, 0.44 mmol) in anhydrous tetrahydrofuran (THF) (5 ml) at Ϫ78°C under nitrogen to prepare a lithium diisopropylamide solution. To this solution, (Ϫ)-multiflorine (100 mg, 0.40 mmol) in THF (3 ml) was added over 30 min and was stirred at Ϫ78°C for 1 h. Phenylselenyl chloride (92 mg, 0.48 mmol) in THF (3 ml) was then added, and the solution was stirred at this temperature for 8 h. The reaction was terminated with water, and the reaction mixture was warmed to room temperature and extracted three times with CH 2 Cl 2 . The CH 2 Cl 2 lay-ers were dried over Na 2 SO 4 , and the solvent was removed in vacuo, resulting in crude 5-phenylselenylmultiflorine. Crude 5-phenylselenylmultiflorine was dissolved in anhydrous CH 2 Cl 2 (3 ml) and cooled to Ϫ60°C. To this solution, mchloroperbenzoic acid (150 mg, 0.66 mmol) in anhydrous CH 2 Cl 2 (3 ml) was then added, and the solution was stirred for 6 h at Ϫ60°C and warmed to room temperature. Water was added to the reaction mixture, and the CH 2 Cl 2 layer was separated out. The aqueous layer was extracted three times with CH 2 Cl 2 . The combined CH 2 Cl 2 layers were dried over Na 2 SO 4 , and the solvent was removed in vacuo. The residue was purified on silica gel column chromatography (solvent system CH 2 Cl 2 : MeOH : 28% NH 4 OHϭ90 : 9 : 1) to yield (Ϫ)-5,6-dehydromultiflorine as a pale yellow oil (yield, 45 mg, 46% Oxalyl chloride (50 mg, 0.40 mmol) in anhydrous CH 2 Cl 2 (3 ml) was cooled to Ϫ78°C, and DMSO (63 mg, 0.8 mmol) was added to the solution. 4-Hydroxysparteine (93 mg, 0.37 mmol) in CH 2 Cl 2 (3 ml) was added to the solution, the solution was stirred at Ϫ78°C for 15 min, and triethylamine (188 mg, 1.86 mmol) was added. After 5 min, the solution was warmed to room temperature, and the reaction was terminated with water. The solution was extracted three times with CH 2 Cl 2 . The combined CH 2 Cl 2 layers were washed with brine, dried over Na 2 SO 4 , and concentrated in vacuo. The residue was purified on silica gel column chromatography (solvent system CH 2 Cl 2 : MeOH : 28% NH 4 OHϭ90 : 9 : 1) to yield (Ϫ)-4-oxo-sparteine (dihydromultiflorine) as a pale yellow oil (yield, 79 mg, 86% Stille Coupling, Bipyridyl (9) 4-Methoxy-2-tributylstannanylpyridine (1420 mg, 3.57 mmol), ethyl 5-bromonicotinate (1642 mg, 7.14 mmol), triphenylphosphine (93 mg, 0.357 mmol), and tetrakis(triphenylphosphine)palladium(0) (206 mg, 0.179 mmol) were dissolved in p-xylene (30 ml) and refluxed under nitrogen for 10 h. After cooling, water was added to the reaction mixture, and the solution made alkaline with NaHCO 3 solution. The xylene layer was removed, and the aqueous solution was extracted twice with CH 2 Cl 2 . The organic layers were combined, dried over Na 2 SO 4 , and the organic solution was removed in vacuo. The residue was purified with silica gel column chromatography (yield, 756 mg, 82%).
Colorless needles. mp 94-97°C. Bipyridyl Alcohol (10) Bipyridyl (9) (565 mg, 2.19 mmol) was dissolved in anhydrous THF (10 ml) and cooled to Ϫ40°C under nitrogen. An equal amount of LiAlH 4 in THF was added to the solution, and the solution was stirred for 1 h. The reaction mixture became an orange suspension. The reaction mixture was allowed to come to room temperature and was then stirred for 3 h. The reaction was terminated with water, and the solution was extracted three times with ethyl acetate. The combined ethyl acetate layers were dried over Na 2 SO 4 , and the solvent was removed to give bipyridyl alcohol (10) as a colorless solid (yield, 300 mg, 63% 3,5 cis-Piperidine (11) Bipyridyl alcohol (10) (580 mg, 2.68 mmol) and benzyl bromide (550 mg, 3.22 mmol) were dissolved in anhydrous acetonitrile (50 ml), and refluxed under a nitrogen atmosphere for 3 h. After cooling, acetonitrile was removed in vacuo to give an N-benzyl pyridinium salt. This compound was utilized for the next reaction without purification. The pyridinium salt in MeOH (100 ml) containing triethylamine (289 mg, 5.72 mmol) was hydrogenated over PtO 2 under 3.5 atm hydrogen pressure for 4 h. The catalyst was removed by filtration, and the solvent was removed in vacuo to give cis-piperidine (11) as a pale yellow oil (yield, 573 mg, 68%).
(1Ј-Benzyl-4-methoxy-1Ј,2Ј,3Ј,4Ј,5Ј,6Ј-hexahydro-[2,3Ј]bipyridinyl-5Ј-yl)-methanol ( Cyclization of 11, N-Benzyl Tricyclic Pyridone (4) The alcohol 11 (100 mg, 0.32 mmol) was dissolved in a 48% HBr solution (5 ml). The solution was refluxed for 12 h. After cooling, the reaction mixture was made akaline with 20% NaOH and extracted three times with CH 2 Cl 2 . The CH 2 Cl 2 layers were combined, dried over Na 2 SO 4 
Deprotection of Compound 4, Secondary Amine 5
Compound 4 (150 mg, 0.53 mmol) in EtOH (10 ml) was hydrogenated over 10% palladium on carbon for 3 d. The catalyst was removed by filtration, and the filtrate was evaporated in vacuo. The residue was purified on silica gel column chromatography (CH 2 Cl 2 : MeOH : 28% NH 4 OHϭ90 : 9 : 1) to yield compound 5 as a colorless oil (yield, 45 mg, 45%). 
N-Methylation, N-Methyl Tricyclic Compound (6)
Secondary amine 5 (56 mg, 0.29 mmol) in EtOH (5 ml) was treated with HCHO (17.4 mg, 0.5 mmol) and NaBH 3 CN (18.2 mg, 0.29 mmol) for 10 h. The solution was made acidic by the addition of 5% HCl solution, and the solution was stirred until there was no further generation of gas. After cooling, the solution was made alkaline with K 2 CO 3 and extracted with CH 2 Cl 2 three times. The CH 2 Cl 2 layers were combined, dried over Na 2 SO 4 , and the solvent was removed in vacuo. The residue was purified on silica gel column chromatography (CH 2 Cl 2 : MeOHϭ9 : 1) to yield compound 6 as a colorless oil (yield, 40 mg, 66%). N-Propyl Tricyclic Compound (8) N-Allyl tricyclic compound 7 (30 mg, 0.13 mmol) in EtOH (5 ml) was hydrogenated over 10% palladium on carbon (8 mg) under ambient pressure. The catalyst was removed by filtration, and the filtrate was concentrated in vacuo. The residue was purified on silica gel column chromatography (CH 2 Cl 2 : MeOHϭ9 : 1) to yield N-propyl tricyclic compounds as a pale yellow oil (yield, 25 mg, 82%). Animals Six-weeks-old male ICR mice (Tokyo Laboratory Animal Science Co., Ltd., Tokyo, Japan), weighing approximately 30 g, were used. The mice had free access to food and water in an animal room that was maintained at 24Ϯ1°C with a 12-h light-dark cycle. Mice were fasted for 12 h prior to oral glucose tolerance testing. Studies were carried out in accordance with the Declaration of Helsinki and/or the Guide for the Care and Use of Laboratory Animals as adopted by the Committee on the Care and Use of Laboratory Animals of Hoshi University, which is accredited by the Japanese Ministry of Education, Culture, Sports, Science and Technology.
(t). HR-EI-MS
The hypoglycemic effect of the compounds were evaluated in a glucose tolerance test. Each mouse was injected intraperitoneally with the test drug, followed by oral administration of a glucose solution (3.0 g/kg). Blood was collected via caudalis venipuncture before the test and 30, 60, 90, 120, 150, and 180 min after injection. The increment ratios of blood glucose levels were calculated for each animal according to the following formula: 100ϫ(postdrug blood glucose levelϪpredrug blood glucose level)/(predrug blood glucose level).
Statistical Analysis Data are expressed as meanϮS.E. The statistical significance of differences was assessed using the Bonferroni-Dunn test. pϽ0.05 was considered statistically significant.
RESULTS AND DISCUSSION
It has been reported that 5,6-dehydromultiflorine can be isolated from L. termis, 4) but we were unable to do so. Therefore (Ϫ)-multiflorine (1) was first transformed to 5-phenylselenylmultiflorine and then treated with m-chloroperbenzoic acid, yielding 5,6-dehydromultiflorine (2) as a 4-pyridonetype alkaloid (Fig. 1) . Dihydromultiflorine (3) was not isolated from L. termis, but was isolated from genus Lupinus plants. 5) This compound was also transformed from (Ϫ)-multiflorine (1) with the following method. (Ϫ)-Multiflorine was treated with platinum oxide-catalyzed hydrogenation to create 4-hydroxysparteine, and the hydroxy group was then oxidized to yield a 4-piperidone-type alkaloid, dihydromultiflorine (3) (Fig. 1) .
The syntheses of tricyclic compounds were similar to that of cytisine (Fig. 2) .
6) 4-Methoxy-2-tributylstannanylpyridine and ethyl 5-bromonicotinate were selected as starting materials. Compound 9 was synthesized by Stille coupling. The ester was reduced with LiAlH 4 to give a dipyridyl alcohol (10). Selective N-benzylation of the nitrogen arising from nicotinate was performed to give a pyridinium salt. The pyridinium salt was hydrogenated over platinum oxide to give 3,5-cis piperidine (11) as a single isomer by NMR. Mesylation of the primary alcohol (11) followed by heating yielded benzyl-protected tricyclic 4-pyridone (4). Hydrogenolysis of compound 4 with a palladium catalyst gave a secondary amine (5) . The secondary amine group in compound 5 was alkylated with methyl iodine and allyl bromide to yield compounds 6 and 7, respectively. Reduction of the double bond in the allyl group of compound 7 reduced with palladium gave an N-propyl amine (8) .
Compounds 1-8 were analyzed in glucose tolerance tests. The time courses of the increment ratios of blood glucose levels for tetracyclic compounds 1, 2 and 3 (30 mg/kg in saline) and tricyclic compounds 4-8 are shown in Figs. 3 and 4, respectively. We selected the dose 30 mg/kg because (Ϫ)-multiflorine (1) began to show a statistically significant from vehicle at that dose.
Among the tetracyclic compounds tested, only compounds 1 and 2 had significant hypoglycemic effects. The chemical structures of these compounds are similar to each other. Thus it appears that double bond(s) in the A-B ring system of multiflorine influence hypoglycemic potency. Among the tricyclic compounds tested, compounds 5 and 6 had significant hypoglycemic effects, similar to that of multiflorine. We suspect that the D ring in (Ϫ)-multiflorine (1) is not necessary for the hypoglycemic effect and that small substituted groups such as a methyl group influence the potency of the hypoglycemic effect.
Cytisine is a common component in leguminuous plants and it behaves as a partial agonist of neuronal nicotinic receptors. 7, 8) However, because of the toxicity of 2-pyridonetype lupine alkaloids, cytisine is not used therapeutically. The administration of (Ϫ)-cytisine (30 mg/kg, intraperitoneally) induced convulsive seizures in mice, and almost all died. Acute toxicity of multiflorine or 5,6-dehydromultiflorine (2) as well as compounds 5 and 6 was not found in this study. Thus the position of the oxo-group in the A-B ring system of multiflorine has hypoglycemic effects with no acute toxicity.
The mechanism of the hypoglycemic effect of the quinolizidin-2-one ring system was not investigated in this study. The quinolizidin-2-one ring system differs in structure from conventional drugs used for the treatment of diabetes and may have therapeutic potential as a new type of diabetes drug. Modifications to improve the potency and administration as well as a detailed study of structure-activity relations of the quinolizidin-2-one ring system are currently under way in our laboratory.
